시장보고서
상품코드
1473241

분자진단약 관련 제휴와 라이선스 계약(2016-2024년)

Molecular Diagnostics Collaboration and Licensing Deals 2016-2024

발행일: | 리서치사: Current Partnering | 페이지 정보: 영문 400+ Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    


※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

분자진단약 관련 최근(2016-2024년) 제휴와 라이선스 계약의 동향에 대해 분석했으며, 전체적인 거래 건수의 추이 및 재무면(지불 조건)의 동향, 주요 기업(총 25사)에 의한 거래 성립의 동향, 계약 조건의 동향, 기술별 상세 동향 등을 조사하고, 최근 주요 제휴 거래의 상세 정보를 정리하여 전해드립니다.

목차

주요 요약

제1장 서론

제2장 분자진단약 관련 거래 성립의 동향

  • 서론
  • 분자진단약 관련 거래의 장기적 동향
  • 분자진단약 관련 거래 : 거래 유형별
  • 분자진단약 관련 가장 활발한 거래업체
  • 분자진단약 관련 거래 : 치료 영역별
  • 분자진단약 관련 거래 : 업계별
  • 분자진단약 관련 거래 : 거래조건
    • 분자진단약 관련 거래 : 거래 총액
    • 분자진단약 관련 거래 : 선불금
    • 분자진단약 관련 거래 : 마일스톤 지불
    • 분자진단약 관련 거래 : 로열티율

제3장 분자진단약 관련 주요 거래

  • 서론
  • 분자진단약 관련 주요 거래 : 계약금액 기반

제4장 분자진단약 관련 가장 활발한 거래 기업

  • 서론
  • 분자진단약 관련 거래에서 가장 활발한 기업
  • 분자진단약 관련 거래에서 가장 활발한 기업 : 개요

제5장 분자진단약 관련 계약 체결 디렉토리

  • 서론
  • 분자진단약 관련 계약 체결 디렉토리

제6장 분자진단약 관련 거래 : 기술 유형별

  • 거래 디렉토리
  • 거래 디렉토리 : 분자진단약 관련, 기업별(ABC순서)
  • 거래 디렉토리 : 분자진단약 관련, 거래 유형별
  • 거래 디렉토리 : 분자진단약 관련, 치료 영역별
  • 거래 유형의 정의
  • Biopharma Research Ltd 소개
  • 현재의 제휴
  • 현재의 계약
  • Current Partnering 간행 최근 리포트 타이틀
KSA 24.05.13

Molecular Diagnostics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the molecular diagnostics deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of molecular diagnostics deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 740 molecular diagnostics deals announced since 2016 including financial terms where available including links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of molecular diagnostics dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in molecular diagnostics dealmaking since 2016.

Chapter 3 provides an overview of the leading molecular diagnostics deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in molecular diagnostics dealmaking with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of molecular diagnostics deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since Jan 2016. The chapter is organized by specific molecular diagnostics technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in molecular diagnostics deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Molecular Diagnostics Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse molecular diagnostics collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, deal type and therapy area
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

  • Molecular Diagnostics Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of molecular diagnostics trends and structure of deals entered into by leading biopharma companies worldwide.

Molecular Diagnostics Collaboration and Licensing Deals includes:

  • Trends in molecular diagnostics dealmaking in the biopharma industry
  • Directory of molecular diagnostics deal records covering pharmaceutical and biotechnology
  • The leading molecular diagnostics deals by value
  • Most active molecular diagnostics licensing dealmakers
  • Molecular Diagnostics Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in molecular diagnostics dealmaking

  • 2.1. Introduction
  • 2.2. Molecular diagnostics deals over the years
  • 2.3. Most active molecular diagnostics dealmakers
  • 2.4. Molecular diagnostics deals by deal type
  • 2.5. Molecular diagnostics deals by therapy area
  • 2.6. Molecular diagnostics deals by industry sector
  • 2.7. Deal terms for molecular diagnostics deals
    • 2.7.1 Molecular diagnostics deals headline values
    • 2.7.2 Molecular diagnostics deal upfront payments
    • 2.7.3 Molecular diagnostics deal milestone payments
    • 2.7.4 Molecular diagnostics royalty rates

Chapter 3 - Leading molecular diagnostics deals

  • 3.1. Introduction
  • 3.2. Top molecular diagnostics deals by value

Chapter 4 - Most active molecular diagnostics dealmakers

  • 4.1. Introduction
  • 4.2. Most active molecular diagnostics dealmakers
  • 4.3. Most active molecular diagnostics deals company profiles

Chapter 5 - Molecular diagnostics contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Molecular diagnostics contracts dealmaking directory

Chapter 6 - Molecular diagnostics dealmaking by technology type

  • Deal directory
  • Deal directory - Molecular diagnostics deals by company A-Z
  • Deal directory - Molecular diagnostics deals by deal type
  • Deal directory - Molecular diagnostics deals by therapy area
  • Deal type definitions
  • About Biopharma Research Ltd
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Molecular diagnostics deals since 2016
  • Figure 2: Active molecular diagnostics dealmaking activity - 2016 - 2024
  • Figure 3: Molecular diagnostics deals by deal type since 2016
  • Figure 4: Molecular diagnostics deals by therapy area since 2016
  • Figure 5: Molecular diagnostics deals by industry sector since 2016
  • Figure 6: Molecular diagnostics deals with a headline value
  • Figure 7: Molecular diagnostics deals with an upfront value
  • Figure 8: Molecular diagnostics deals with a milestone value
  • Figure 9: Molecular diagnostics deals with a royalty rate value
  • Figure 10: Top molecular diagnostics deals by value since 2016
  • Figure 11: Most active molecular diagnostics dealmakers 2016 - 2024
  • Figure 12: Molecular diagnostics deals by technology type since 2016
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제